Healthcare · Medical Specialties
Danaher Corporation
$234.92 -0.39 (-0.17%) Pre-market $234.40 (-0.39%) ≈ ₹22,048 a share
Key numbers
- Market value
- $165.27B
- P/E (TTM)
- 38.8
- Forward P/E
- 26.8
- EPS (TTM)
- $6.05
- Dividend yield
- 0.68%
- Beta
- 0.78
- Day range
- $232.25 – $235.66
- 52-week range
- $160.93 – $242.80
- Volume
- 682,382
- 10-day avg volume
- $3.48M
- Revenue (TTM)
- $25.61B
- EBITDA (TTM)
- $8.12B
- Gross margin
- 58.9%
- Net margin
- 16.8%
- Return on equity
- 8.2%
- Debt / equity
- 49.4%
- Price / sales
- 6.45
- Shares out
- 703.53M
Quarterly results
Results for each quarter
Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.
Revenue and net income
Revenue · QoQ (vs last quarter)
Revenue · YoY (vs a year ago)
Net income · QoQ (vs last quarter)
Net income · YoY (vs a year ago)
| US$ | Dec 23 | Mar 24 | Jun 24 | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.41B | $5.80B | $5.74B | $5.80B | $6.54B | $5.74B | $5.94B | $6.05B | $6.84B | $5.95B | $6.27B | $6.55B |
| Cost of revenue | $2.63B | $2.31B | $2.32B | $2.40B | $2.65B | $2.23B | $2.41B | $2.53B | $2.87B | $2.36B | $2.65B | $2.72B |
| Gross profit | $3.78B | $3.49B | $3.43B | $3.40B | $3.89B | $3.51B | $3.52B | $3.52B | $3.97B | $3.59B | $3.61B | $3.84B |
| Gross margin | 59.0% | 60.2% | 59.7% | 58.7% | 59.5% | 61.2% | 59.3% | 58.2% | 58.0% | 60.3% | 57.6% | 58.5% |
| Research & development | $407.00M | $368.00M | $391.00M | $383.00M | $442.00M | $379.00M | $403.00M | $378.00M | $438.00M | $387.00M | $412.00M | $433.00M |
| Selling, general & admin | $2.04B | $1.81B | $1.87B | $2.06B | $2.02B | $1.86B | $2.36B | $1.99B | $2.03B | $1.86B | $2.07B | $2.16B |
| Operating income | $1.34B | $1.31B | $1.17B | $958.00M | $1.43B | $1.27B | $760.00M | $1.15B | $1.50B | $1.34B | $1.13B | $1.25B |
| Operating margin | 20.9% | 22.6% | 20.3% | 16.5% | 21.8% | 22.2% | 12.8% | 19.1% | 22.0% | 22.6% | 18.0% | 19.0% |
| Interest expense | $80.00M | $65.00M | $65.00M | $87.00M | $61.00M | $72.00M | $71.00M | $67.00M | $55.00M | $63.00M | $107.00M | $135.00M |
| Pre-tax income | $1.23B | $1.27B | $1.08B | $977.00M | $1.32B | $1.13B | $655.00M | $1.08B | $1.37B | $1.24B | $1.08B | $1.13B |
| Income tax | $111.00M | $183.00M | $176.00M | $159.00M | $229.00M | $175.00M | $100.00M | $168.00M | $190.00M | $206.00M | $208.00M | $-75.00M |
| Net income | $1.08B | $1.09B | $907.00M | $818.00M | $1.09B | $954.00M | $555.00M | $908.00M | $1.20B | $1.03B | $870.00M | $1.24B |
| Net margin | 16.8% | 18.8% | 15.8% | 14.1% | 16.6% | 16.6% | 9.3% | 15.0% | 17.5% | 17.3% | 13.9% | 18.8% |
| EPS (diluted) | $1.45 | $1.45 | $1.22 | $1.12 | — | $1.32 | $0.77 | $1.27 | — | $1.45 | $1.23 | $1.75 |
Income statement
Results for each year
8 fiscal years from the company's 10-K filings with the US SEC.
Revenue, gross profit and net income
Revenue · YoY (vs a year ago)
Net income · YoY (vs a year ago)
EPS (diluted) · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.89B | $17.91B | $22.28B | $24.80B | $26.64B | $23.89B | $23.88B | $24.57B |
| Revenue growth | — | -10.0% | 24.4% | 11.3% | 7.4% | -10.3% | -0.1% | 2.9% |
| Cost of revenue | $7.54B | $7.93B | $9.81B | $9.56B | $10.46B | $9.86B | $9.67B | $10.05B |
| Gross profit | $9.51B | $9.98B | $12.48B | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B |
| Gross margin | 47.8% | 55.7% | 56.0% | 61.4% | 60.8% | 58.7% | 59.5% | 59.1% |
| Research & development | $1.06B | $1.13B | $1.35B | $1.50B | $1.53B | $1.50B | $1.58B | $1.60B |
| Selling, general & admin | $5.39B | $5.59B | $6.90B | $6.82B | $7.12B | $7.33B | $7.76B | $8.24B |
| Operating income | $3.06B | $3.27B | $4.23B | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B |
| Operating margin | 15.4% | 18.3% | 19.0% | 25.7% | 28.3% | 21.8% | 20.4% | 19.1% |
| Depreciation & amortisation | $1.18B | $1.19B | $1.78B | $2.06B | $2.13B | $2.17B | — | — |
| Interest expense | $137.00M | $108.00M | $275.00M | $231.00M | $204.00M | $286.00M | $278.00M | $265.00M |
| Pre-tax income | $2.96B | $3.31B | $4.50B | $6.51B | $7.15B | $5.04B | $4.65B | $4.23B |
| Income tax | $556.00M | $873.00M | $849.00M | $1.06B | $818.00M | $823.00M | $747.00M | $633.00M |
| Tax rate | 18.8% | 26.4% | 18.9% | 16.3% | 11.4% | 16.3% | 16.1% | 15.0% |
| Net income | $2.65B | $3.01B | $3.65B | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B |
| Net margin | 13.3% | 16.8% | 16.4% | 25.9% | 27.1% | 19.9% | 16.3% | 14.7% |
| EPS (diluted) | $3.74 | $4.05 | $4.89 | $8.61 | $9.66 | $6.38 | $5.29 | $5.05 |
Balance sheet
Assets and debt
At each fiscal year end.
Equity, debt and cash
Shareholders' equity · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $787.80M | $19.91B | $6.04B | $2.59B | $6.00B | $5.86B | $2.08B | $4.62B |
| Current assets | $7.09B | $25.60B | $13.80B | $11.65B | $15.88B | $13.94B | $9.50B | $12.76B |
| Total assets | $47.83B | $62.08B | $76.16B | $83.18B | $84.35B | $84.49B | $77.54B | $83.46B |
| Current liabilities | $4.84B | $4.93B | $7.40B | $8.14B | $8.39B | $8.27B | $6.80B | $6.81B |
| Long-term debt | $9.69B | $21.52B | $21.19B | $22.17B | $19.09B | $16.71B | $15.50B | $18.42B |
| Short-term debt | $51.80M | $212.00M | $11.00M | $8.00M | $591.00M | $1.70B | $505.00M | $2.00M |
| Total debt | $9.74B | $21.73B | $21.20B | $22.18B | $19.68B | $18.40B | $16.01B | $18.42B |
| Shareholders' equity | $28.21B | $30.27B | $39.77B | $45.17B | $50.08B | $53.49B | $49.54B | $52.53B |
| Current ratio | 1.47 | 5.19 | 1.86 | 1.43 | 1.89 | 1.68 | 1.40 | 1.87 |
| Debt / equity | 0.35 | 0.72 | 0.53 | 0.49 | 0.39 | 0.34 | 0.32 | 0.35 |
| Return on equity | 9.4% | 9.9% | 9.2% | 14.2% | 14.4% | 8.9% | 7.9% | 6.9% |
Cash flow
Cash coming in and going out
Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.
Free cash flow and shareholder returns
Operating cash flow · YoY (vs a year ago)
Free cash flow · YoY (vs a year ago)
| US$ | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | $4.02B | $3.95B | $6.21B | $8.36B | $8.52B | $7.16B | $6.69B | $6.42B |
| Capital spending | $-584.00M | $-636.00M | $-791.00M | $-1.24B | $-1.12B | $-1.38B | $-1.39B | $-1.16B |
| Free cash flow | $3.44B | $3.32B | $5.42B | $7.12B | $7.40B | $5.78B | $5.30B | $5.26B |
| FCF margin | 17.3% | 18.5% | 24.3% | 28.7% | 27.8% | 24.2% | 22.2% | 21.4% |
| Stock-based pay | $138.00M | $159.00M | $187.00M | $184.00M | $295.00M | $306.00M | $288.00M | $298.00M |
| Cash from investing | $-2.95B | $-1.24B | $-21.24B | $-12.99B | $-2.23B | $-7.08B | $-1.98B | $-1.20B |
| Cash from financing | $-797.00M | $16.37B | $1.01B | $1.30B | $-2.57B | $-273.00M | $-8.39B | $-2.96B |
| Dividends paid | $-433.00M | $-527.00M | $-615.00M | $-742.00M | $-818.00M | $-821.00M | $-768.00M | $-878.00M |
| Share buybacks | — | — | — | — | $0 | $0 | $-5.98B | $-3.09B |
About
About Danaher Corporation
Danaher Corporation is an American healthcare company headquartered in Washington, D.C.. It develops products used for advances in biotechnology, life sciences, and diagnostics. The company operates three divisions: biotechnology, which develops products for the development of therapeutics; life sciences, which develops products to identify causes of disease, new therapies, and to test and manufacture new drugs, vaccines and gene editing technologies; and diagnostics, which develops instruments, consumables, and software and services to diagnose diseases. Danaher was founded in 1984 by brothers Steven Rales and Mitchell Rales; it was named after Danaher Creek in Western Montana, where the brothers came up with the idea for the company while fishing.
From Wikipedia (CC BY-SA 4.0).
Company details
- Company name
- Danaher Corporation
- Ticker
- DHR
- Exchange
- NYSE
- ISIN
- US2358511028
- SEC CIK
- 0000313616
- Sector
- Healthcare
- Industry
- Medical Specialties
- SEC industry (SIC)
- Industrial Instruments For Measurement, Display, And Control (3823)
- Incorporated in
- Delaware
- Financial year ends
- 31 December
- Filer type
- Large accelerated filer
- Latest annual report (10-K)
- 24 Feb 2026
- CEO
- Julie Sawyer Montgomery
- Chair
- Steven M. Rales
- Headquarters
- Washington, D.C.
- Address
- 2200 Pennsylvania Ave. N.w., Suite 800w, Washington, Dc 20037-1701
- Founded
- 1984
- Employees
- 60,000
- Trades in
- US dollars (USD)
- Website
- danaher.com
News
Latest news
From Google News; each link opens the publisher's story.
Peers
Others in Healthcare
Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.